Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $406.31 Million Stock Position in Danaher Co. (NYSE:DHR)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its stake in shares of Danaher Co. (NYSE:DHR - Free Report) by 1.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,693,586 shares of the conglomerate's stock after selling 19,945 shares during the quarter. Danaher makes up 4.0% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's portfolio, making the stock its 6th largest position. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned 0.23% of Danaher worth $406,308,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Wellington Management Group LLP increased its position in Danaher by 18.6% during the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate's stock valued at $6,185,203,000 after purchasing an additional 3,905,449 shares during the period. Allen Investment Management LLC increased its position in Danaher by 1,440.7% during the 3rd quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate's stock valued at $273,009,000 after purchasing an additional 1,028,976 shares during the period. J.P. Morgan Private Wealth Advisors LLC purchased a new position in Danaher during the 3rd quarter valued at about $178,850,000. Alecta Tjanstepension Omsesidigt purchased a new position in Danaher during the 4th quarter valued at about $161,994,000. Finally, Harris Associates L P increased its position in Danaher by 27.7% during the 3rd quarter. Harris Associates L P now owns 2,963,899 shares of the conglomerate's stock valued at $735,343,000 after purchasing an additional 642,759 shares during the period. Institutional investors own 79.05% of the company's stock.

Danaher Stock Performance

NYSE DHR traded up $0.57 on Monday, hitting $236.08. 2,809,648 shares of the company's stock traded hands, compared to its average volume of 2,724,488. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $259.00. The firm's 50-day moving average price is $248.72 and its two-hundred day moving average price is $230.39. The firm has a market capitalization of $174.83 billion, a PE ratio of 36.95, a P/E/G ratio of 3.95 and a beta of 0.83.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, beating the consensus estimate of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The business had revenue of $6.41 billion during the quarter, compared to analysts' expectations of $6.10 billion. During the same period in the previous year, the business posted $2.87 EPS. The business's quarterly revenue was down 10.2% compared to the same quarter last year. As a group, analysts expect that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.46%. This is a boost from Danaher's previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher's payout ratio is presently 16.90%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on DHR shares. StockNews.com downgraded shares of Danaher from a "buy" rating to a "hold" rating in a research report on Wednesday, January 31st. KeyCorp lifted their price objective on shares of Danaher from $260.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, February 1st. Royal Bank of Canada lifted their price objective on shares of Danaher from $254.00 to $282.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 31st. Barclays lifted their price objective on shares of Danaher from $240.00 to $260.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 10th. Finally, Citigroup lifted their price objective on shares of Danaher from $255.00 to $280.00 and gave the stock a "buy" rating in a research report on Wednesday, January 31st. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, Danaher has an average rating of "Moderate Buy" and a consensus target price of $268.27.

Insider Activity at Danaher

In related news, SVP Daniel Raskas sold 23,757 shares of the business's stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, SVP Daniel Raskas sold 23,757 shares of the business's stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of the business's stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares of the company's stock, valued at $1,029,891.48. The disclosure for this sale can be found here. Insiders sold a total of 32,957 shares of company stock worth $8,265,802 in the last three months. Company insiders own 10.90% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.